 |
|
|
| |
Analysis of Efficacy by Baseline HIV RNA - Week 48 Results from a Phase 3 Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) Compared to Efavirenz/Emtricitabine/Tenofovir DF in Treatment Na•ve HIV-1 Infected Subjects
|
| |
| |
Reported by Jules Levin
IAC July 22-27 2012 Wash DC
P Sax1, E DeJesus2, A Mills3, A Zolopa4, C Cohen5, D Wohl6, JE Gallant7, HC Liu8, L Zhong8, K Yale8, K White8, B Kearney8, J Szwarcberg8, E Quirk8, and A Cheng8
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 2Orlando Immunology Center, Orlando, FL, US; 3Anthony Mills MD, Inc., Los Angeles, US; 4Stanford University, Palo Alto, CA, US; 5Community Research Initiative of New England, Boston, MA, US; 6University of North Carolina, Chapel Hill, NC, US; 7Johns Hopkins School of Medicine, Baltimore, MD, US; 8Gilead Sciences, Foster City, CA, US
|
| |
|
|
|
|
|
